|By Marketwired .||
|April 9, 2014 07:45 AM EDT||
NEWARK, NJ -- (Marketwired) -- 04/09/14 -- BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU) today announced that it has entered into Sales and Distribution Agreement with Menzer Ltd. for distribution of our OGIENE line of odor elimination and cleaning products in the United Kingdom, Europe and the Middle East.
This agreement is another component of our slate of channel partners that we are strategically aligning ourselves with. Initially Menzer will focus on sales of our OGIENE products for consumer use by distributing to chain store retailers. Menzer also plans to offer our OGIENE line commercially.
"We are delighted to be able to offer our customers in Europe the innovative technology OGIENE provides," said Scott Dougan, director of Menzer. "OGIENE will bring something new to the marketplace and we are confident the highly effective range of Odor eliminators and Multipurpose Cleansers will attract consumers across Europe."
"We are pleased to have Menzer on board to begin our initial commercialization effort at the consumer level," said Mark Lowenthal, President and CEO for BioNeutral. "Our OGIENE line of odor eliminators and cleaning products carry our unique and proprietary combinational chemistries offering superior performance that we feel will the consumer will respond to. Gaining access to store shelves in the UK and Europe should be a great start for us."
About Menzer Ltd.
Menzer Ltd is company registered in England and Wales located in Evesham, England focused on the sale and distribution of consumer and industrial specialty chemical products. Find Menzer at www.ogiene.co.uk
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE and OGIENE, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the YGIENE brand have been approved by the EPA for sale in the United States. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.
CONTACT FOR THE COMPANY:
BioNeutral Group, Inc.
Jul. 23, 2016 05:00 PM EDT Reads: 1,775
Jul. 23, 2016 05:00 PM EDT Reads: 923
Jul. 23, 2016 04:45 PM EDT Reads: 885
Jul. 23, 2016 04:30 PM EDT Reads: 654
Jul. 23, 2016 04:00 PM EDT Reads: 2,290
Jul. 23, 2016 04:00 PM EDT Reads: 1,801
Jul. 23, 2016 04:00 PM EDT Reads: 1,963
Jul. 23, 2016 03:45 PM EDT Reads: 1,488
Jul. 23, 2016 03:30 PM EDT Reads: 1,828
Jul. 23, 2016 03:15 PM EDT Reads: 768
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Jul. 23, 2016 03:00 PM EDT Reads: 1,643
Jul. 23, 2016 03:00 PM EDT Reads: 1,176
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
Jul. 23, 2016 02:30 PM EDT Reads: 1,696
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Jul. 23, 2016 02:15 PM EDT Reads: 617
Venafi has extended the power of its platform in an easy-to-use utility for DevOps teams available for immediate download. Now DevOps teams can eliminate the hassle of acquiring and installing TLS keys and certificates. Instead, customers can focus on speeding up continuous development and deployment, while security teams have complete visibility and can keep the DevOps environment secure and compliant to protect customer data. Extending the Venafi Trust Protection Platform requires only a singl...
Jul. 23, 2016 02:00 PM EDT Reads: 999